AREDS2 Supplement Formula: Complete Guide for AMD

The AREDS2 formula is one of the most rigorously tested supplement protocols in ophthalmology. Born from two large National Eye Institute clinical trials spanning over a decade, it represents a rare case where a specific nutrient combination was tested in a randomized controlled trial and found to reduce the risk of vision loss. Yet misconceptions persist about who should take it, what it contains, and whether all AREDS2-labeled products are equivalent.

How the AREDS Trials Shaped the Formula

The original AREDS trial (Age-Related Eye Disease Study) ran from 1992 to 2001 and enrolled over 4,700 participants. It tested a combination of beta-carotene (15 mg), vitamin C (500 mg), vitamin E (400 IU), zinc (80 mg), and copper (2 mg). The result was a 25% reduction in the progression to advanced AMD over five years among those with intermediate disease.

AREDS2, published in 2013, set out to improve the formula. Researchers tested whether replacing beta-carotene with lutein and zeaxanthin, and whether adding omega-3 fatty acids (DHA 350 mg and EPA 650 mg), improved outcomes further. The trial enrolled 4,203 participants and ran for five years. The primary finding: lutein and zeaxanthin were at least as effective as beta-carotene for AMD protection, and critically, they did not raise lung cancer risk in smokers. Omega-3s did not significantly improve the primary AMD outcome.

Breaking Down Each Ingredient

Vitamin C (500 mg): Roughly five times the RDA, vitamin C is a primary water-soluble antioxidant in the aqueous humor of the eye. The lens and retina are highly metabolically active and generate significant oxidative stress. High-dose vitamin C scavenges free radicals before they damage photoreceptors and retinal pigment epithelium cells.

Vitamin E (400 IU): A fat-soluble antioxidant that protects cell membranes throughout the retina. At this dose it complements vitamin C in a network antioxidant system. Note that 400 IU is higher than some cardiovascular guidelines recommend long-term, so individuals with bleeding disorders or on anticoagulants should discuss this with their physician.

Zinc (80 mg): Zinc is highly concentrated in the retinal pigment epithelium and choroid. It is a cofactor for superoxide dismutase and other antioxidant enzymes. The 80 mg dose is the best-tested, though some clinicians use 25 mg given the AREDS2 secondary analysis showing comparable efficacy at lower doses with better GI tolerability.

Copper (2 mg): Included specifically to counteract the copper deficiency that high-dose zinc can induce by competing for intestinal absorption. Without it, the formula could cause anemia and neurological problems over time.

Lutein (10 mg) and Zeaxanthin (2 mg): These xanthophyll carotenoids are the only ones that selectively accumulate in the macula, forming the macular pigment. They absorb high-energy blue light before it reaches the photoreceptors and directly quench reactive oxygen species. The 10 mg and 2 mg doses reflect the ratio found in the macula and align with the amounts that increased macular pigment optical density in supplementation studies.

Why Beta-Carotene Was Removed

Beta-carotene is converted to vitamin A in the body and was included in the original AREDS formula as an antioxidant. However, two large trials (CARET and ATBC) in the 1990s showed that beta-carotene supplementation at high doses increased lung cancer risk in current and former smokers by approximately 20 to 28%. Since AMD predominantly affects older adults, many of whom have smoking histories, replacing beta-carotene was essential. Lutein and zeaxanthin were the natural replacements given their specific role in macular function.

Reading AREDS2 Labels: Not All Products Are Equal

The term AREDS2 on a label does not guarantee the formula matches the trial. Manufacturers sometimes include partial doses, substitute ingredients, or add unrelated nutrients. To verify a product, check that it contains all six ingredients at the correct doses: vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg (or 25 mg), copper 2 mg, lutein 10 mg, and zeaxanthin 2 mg.

PreserVision AREDS2 by Bausch and Lomb is the original brand used in the trial. Many store-brand generics at major pharmacy chains match the formula at lower cost. Softgel formulations tend to have better absorption for fat-soluble ingredients like lutein, zeaxanthin, and vitamin E than hard capsule versions.

Practical Considerations

Take AREDS2 supplements with a meal containing some fat to optimize absorption of the fat-soluble ingredients. If GI upset occurs with zinc at 80 mg, ask your retinal specialist about switching to a 25 mg formulation. Do not combine with a separate high-dose multivitamin, as this could push some nutrients into excess ranges. Annual blood monitoring of copper and zinc levels is prudent on long-term high-dose zinc.

FAQ

Q: Should I start AREDS2 supplements as a preventive measure before any AMD diagnosis?

No. The evidence base is specific to intermediate and advanced AMD. Taking high-dose zinc without this indication carries risk without proven benefit.

Q: Is it safe to take AREDS2 supplements long-term?

The AREDS2 trial ran for five years and found no serious safety signals for the current formula excluding beta-carotene. Long-term use beyond five years has not been studied in a controlled trial, but most retinal specialists continue recommending it indefinitely for qualifying patients given the ongoing risk of progression.

Q: Can I get the same effect from diet alone?

Diet can supply meaningful amounts of lutein, zeaxanthin, and other antioxidants, but reaching the specific therapeutic doses used in AREDS2 through food alone is impractical. Supplementation is additive to, not a replacement for, a nutrient-dense diet.

Track your supplements in Optimize.